RU2019119857A - Антитела к компоненту комплемента c5 - Google Patents

Антитела к компоненту комплемента c5 Download PDF

Info

Publication number
RU2019119857A
RU2019119857A RU2019119857A RU2019119857A RU2019119857A RU 2019119857 A RU2019119857 A RU 2019119857A RU 2019119857 A RU2019119857 A RU 2019119857A RU 2019119857 A RU2019119857 A RU 2019119857A RU 2019119857 A RU2019119857 A RU 2019119857A
Authority
RU
Russia
Prior art keywords
seq
group
antibody
sequence
amino acid
Prior art date
Application number
RU2019119857A
Other languages
English (en)
Inventor
Питер С. БАЦИУ
Яньбинь ЛЯН
Джейсон ГУ
Мэтью БЕРНЕТТ
Умеш МУЧХАЛ
Джон ДЕСЖАРЛАЙС
Original Assignee
Аллерган, Инк.
Ксенкор, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аллерган, Инк., Ксенкор, Инк. filed Critical Аллерган, Инк.
Publication of RU2019119857A publication Critical patent/RU2019119857A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (10)

1.     Молекула нуклеиновой кислоты, кодирующая антитело к С5, которое связывается с С5 и ингибирует комплемент-зависимый гемолиз, но не блокирует образование С5а, где антитело содержит первую аминокислотную последовательность и вторую аминокислотную последовательность, причем:
(а) первая последовательность содержит:
(i) CDR1, выбранную из группы, состоящей из SEQ ID NO: 13, 19, 25, 31, 37 и 43;
(ii) CDR2, выбранную из группы, состоящей из аминокислотных последовательностей GTS (SEQ ID NOS: 14 и 20), SGS (SEQ ID NO: 26), RTS (SEQ ID NO: 32), YTS (SEQ ID NO: 38) и WAS (SEQ ID NO: 44); и
(iii) CDR3, выбранную из группы, состоящей из SEQ ID NO: 15, 21, 27, 33, 39 и 45; и
(б) вторую последовательность, содержащую
(i) CDR1, выбранную из группы, состоящей из SEQ ID NO: 16, 22, 28, 34, 40 и 46;
(ii) CDR2, выбранную из группы, состоящей из SEQ ID NO: 17, 23, 29, 35, 41 и 47; и
(iii) CDR3, выбранную из группы, состоящей из SEQ ID NO: 18, 24, 30, 36, 42 и 48.
2.     Молекула нуклеиновой кислоты по п. 1, которая функционально связана с регуляторной последовательностью.
RU2019119857A 2014-02-20 2015-02-19 Антитела к компоненту комплемента c5 RU2019119857A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461768374P 2014-02-20 2014-02-20
US61/768.374 2014-02-20
US201461944943P 2014-02-26 2014-02-26
US61/944.943 2014-02-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2016137110A Division RU2693430C2 (ru) 2014-02-20 2015-02-19 Антитела к компоненту комплемента с5

Publications (1)

Publication Number Publication Date
RU2019119857A true RU2019119857A (ru) 2019-07-12

Family

ID=52629696

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2016137110A RU2693430C2 (ru) 2014-02-20 2015-02-19 Антитела к компоненту комплемента с5
RU2019119857A RU2019119857A (ru) 2014-02-20 2015-02-19 Антитела к компоненту комплемента c5
RU2019119862A RU2019119862A (ru) 2014-02-20 2015-02-19 Антитела к компоненту комплемента c5

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2016137110A RU2693430C2 (ru) 2014-02-20 2015-02-19 Антитела к компоненту комплемента с5

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2019119862A RU2019119862A (ru) 2014-02-20 2015-02-19 Антитела к компоненту комплемента c5

Country Status (10)

Country Link
US (4) US9701743B2 (ru)
EP (3) EP3107935B1 (ru)
JP (4) JP6619745B2 (ru)
KR (1) KR102472816B1 (ru)
AU (2) AU2015218903B2 (ru)
CA (2) CA3177696A1 (ru)
IL (2) IL247299B (ru)
RU (3) RU2693430C2 (ru)
SG (1) SG11201606842RA (ru)
WO (1) WO2015127134A2 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
HUE029635T2 (en) 2007-09-26 2017-03-28 Chugai Pharmaceutical Co Ltd A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
EP3107935B1 (en) * 2014-02-20 2020-06-24 Allergan, Inc. Complement component c5 antibodies
HUE050921T2 (hu) * 2014-02-26 2021-01-28 Allergan Inc C5 komplementkomponens antitestek
PL3233921T3 (pl) 2014-12-19 2022-01-10 Chugai Seiyaku Kabushiki Kaisha Przeciwciała anty-c5 i sposoby ich stosowania
FI3390442T3 (fi) * 2015-12-18 2023-11-10 Chugai Pharmaceutical Co Ltd Anti-C5-vasta-aineita ja käyttömenetelmiä
SI3468990T1 (sl) 2016-06-14 2024-07-31 Regeneron Pharmaceuticals, Inc. Protitelesa proti-C in njihove uporabe
KR102538749B1 (ko) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
EA201992091A1 (ru) * 2017-03-06 2020-02-04 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Анти-c5 антитела и их применение
AU2017432640B2 (en) 2017-09-22 2023-11-30 Vectura Inc. Dry powder compositions with magnesium stearate
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
MX2020006113A (es) 2017-12-13 2020-08-24 Regeneron Pharma Combinaciones de anticuerpos anti-c5 y usos de las mismas.
KR20210055742A (ko) 2018-09-06 2021-05-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 인간화된 항-c5 항체 및 이의 용도
WO2020053206A1 (en) * 2018-09-10 2020-03-19 Volution Immuno Pharmaceuticals Sa Coversin for use in the treatment of rheumatic diseases

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
AU606383B2 (en) 1987-03-06 1991-02-07 Research Triangle Institute Polymer blends for selective biodegradability
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1992015673A1 (en) 1991-03-11 1992-09-17 The University Of Georgia Research Foundation, Inc. Cloning and expression of renilla luciferase
ES2313867T3 (es) 1991-12-02 2009-03-16 Medical Research Council Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos.
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
ATE400651T1 (de) 1993-09-10 2008-07-15 Univ Columbia Verwendung von grünem fluoreszenzprotein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
EP0831854A4 (en) 1995-06-06 2001-01-24 Isis Pharmaceuticals Inc OLIGONUCLEOTIDS WITH PHOSPHOROTHIOATE BINDINGS OF HIGH CHIRAL PURITY
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6458547B1 (en) 1996-12-12 2002-10-01 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
EP2135879A3 (en) 2002-06-28 2010-06-23 Domantis Limited Ligand
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP1697741A4 (en) 2003-12-04 2008-02-13 Xencor Inc PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF
ZA200707420B (en) * 2005-02-14 2009-04-29 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
CA2742802C (en) * 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
WO2013180295A1 (ja) 2012-06-01 2013-12-05 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
WO2014110438A1 (en) 2013-01-11 2014-07-17 Alexion Pharmaceuticals, Inc. Compounds and methods related to the c5d domain of complement component c5
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
EP3107935B1 (en) * 2014-02-20 2020-06-24 Allergan, Inc. Complement component c5 antibodies
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
KR102472816B1 (ko) 2022-11-30
CA3177696A1 (en) 2015-08-27
JP2020040965A (ja) 2020-03-19
CA2939626C (en) 2023-01-17
IL288456A (en) 2022-01-01
JP6941148B2 (ja) 2021-09-29
JP6619745B2 (ja) 2019-12-11
EP3107935A2 (en) 2016-12-28
SG11201606842RA (en) 2016-09-29
RU2019119862A (ru) 2019-07-15
US20180222969A1 (en) 2018-08-09
US9701743B2 (en) 2017-07-11
IL247299B (en) 2021-12-01
JP2023021118A (ja) 2023-02-09
WO2015127134A3 (en) 2015-11-05
EP3107935B1 (en) 2020-06-24
US20170306007A1 (en) 2017-10-26
IL247299A0 (en) 2016-09-29
US20150239966A1 (en) 2015-08-27
RU2016137110A (ru) 2018-03-21
AU2015218903B2 (en) 2020-10-15
CA2939626A1 (en) 2015-08-27
EP3653643A1 (en) 2020-05-20
RU2019119862A3 (ru) 2022-01-24
US20210101965A1 (en) 2021-04-08
AU2021200234B2 (en) 2024-02-15
EP4008726A1 (en) 2022-06-08
RU2693430C2 (ru) 2019-07-02
WO2015127134A2 (en) 2015-08-27
KR20160127038A (ko) 2016-11-02
US9932395B2 (en) 2018-04-03
AU2021200234A1 (en) 2021-03-18
JP2017522857A (ja) 2017-08-17
AU2015218903A1 (en) 2016-09-15
US10752678B2 (en) 2020-08-25
JP2021193106A (ja) 2021-12-23

Similar Documents

Publication Publication Date Title
RU2019119857A (ru) Антитела к компоненту комплемента c5
RU2018132044A (ru) Антитела против тау
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
AR105026A1 (es) ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
CO2018004532A2 (es) Anticuerpos anti-cd19 humano con alta afinidad
RU2017128882A (ru) Антитела к биотину и способы их применения
RU2018146533A (ru) Антитела к cd40 и пути их применения
PH12018500708A1 (en) Humanized anti-human cd19 antibodies and methods of use
EP4252769A3 (en) Anti-complement factor c1q antibodies and uses thereof
JP2016063812A5 (ru)
NZ711451A (en) Anti-c5 antibodies having improved pharmacokinetics
RU2018133708A (ru) Антитела, обладающие специфичностью к btla, и их использование
MX2017005987A (es) Anticuerpos anti-interleucina(il)-1beta y metodos de uso.
EA201591153A1 (ru) Антитела, связывающиеся с tl1a, и их применение
RU2017145268A (ru) Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов
JP2014518898A5 (ru)
RU2018130986A (ru) Антитела к jagged и способы их применения
JP2014534237A5 (ru)
JP2016530223A5 (ru)
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
EA201270701A1 (ru) Ингибирующие металлопротеины антитела
AR114281A1 (es) Anticuerpos anti-klk5 y métodos de uso
RU2014127287A (ru) Антитела, используемые для пассивной вакцинации против гриппа
RU2017134043A (ru) Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью
EA201790236A1 (ru) Антитела против vasa и способы их получения и использования